Activation of Cannabinoid Receptor Type II by AM1241 Ameliorates Myocardial Fibrosis via Nrf2-Mediated Inhibition of TGF-β1/Smad3 Pathway in Myocardial Infarction Mice

Cellular Physiology and Biochemistry

Volumn 39, Issue 4, 2016, Pages 1521-1536

  Li, Xiang ^a,b   Han, Dong ^a,b   Tian, Zuhong ^a   Gao, Beilei ^a   Fan, Miaomiao ^a   Li, Congye ^a   Li, Xiujuan ^a   Wang, Yabin ^b   Ma, Sai ^a   Cao, Feng ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cannabinoid receptor II; Fibrosis; Myocardial Infarction; Nrf2; Smad3; TGF 1

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD PROTEIN; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1; CANNABINOID; CANNABINOID 2 RECEPTOR; NFE2L2 PROTEIN, MOUSE; PROTEASE NEXIN I; SERPINE2 PROTEIN, MOUSE; SMAD3 PROTEIN; SMAD3 PROTEIN, MOUSE; TGFB1 PROTEIN, MOUSE; TIMP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEART FIBROBLAST; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIAC MUSCLE; DRUG EFFECTS; FIBROBLAST; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PRIMARY CELL CULTURE;

ANIMALS; CANNABINOIDS; COLLAGEN TYPE I; COLLAGEN TYPE III; FIBROBLASTS; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; NF-E2-RELATED FACTOR 2; PRIMARY CELL CULTURE; RECEPTOR, CANNABINOID, CB2; RNA, SMALL INTERFERING; SERPIN E2; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84988344422     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000447855     Document Type: Article

References (57)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JR Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, 3rd, Moy CS, Muntner R Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, TowfighiA, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American HeartAssociation Statistics C, Stroke Statistics S: Heart disease and stroke statistics-2016 update: A report from the american heart association. Circulation 2016; 133: e38-e360.
2. Jugdutt BI: Limiting fibrosis after myocardial infarction. N Engl J Med 2009; 360: 1567-1569.
3. de Haas HJ, Arbustini E, Fuster V, Kramer CM, Narula J: Molecular imaging of the cardiac extracellular matrix. Circ Res 2014; 114: 903-915.
4. Tamargo J, Lopez-Sendon J: Novel therapeutic targets for the treatment ofheart failure. Nat Rev Drug Discov2011; 10: 536-555.
5. Di Marzo V, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-784.
6. Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, JimenezW: Regression of fibrosis after chronic stimulation of cannabinoid cb2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324: 475-483.
7. Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, ZimmerA, Distler 0, Schett G, Distler JH: The cannabinoid receptor cb2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009; 60: 1129-1136.
8. Hochhauser E, Lahat E, Sultan M, Pappo 0, Waldman M, Same Y, Shainberg A, Gutman M, Safran M, Ari ZB: Ultra low dose delta 9-tetrahydrocannabinol protects mouse liver from ischemia reperfusion injury. Cell Physiol Biochem 2015; 36: 1971-1981.
9. Mukhopadhyay R Rajesh M, Pan H, Patel V, Mukhopadhyay B, Batkai S, Gao B, Hasko G, Pacher P: Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 2010; 48: 457-467.
10. Rajesh M, Pan H, Mukhopadhyay R Batkai S, Osei-Hyiaman D, Hasko G, Liaudet L, Gao B, Pacher P: Pivotal advance: Cannabinoid-2 receptor agonist hu-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 2007; 82: 1382-1389.
11. Wang Y, Ma S, Wang Q, Hu W, Wang D, Li X, Su T, Qin X, Zhang X, Ma K, Chen J, Xiong L, Cao F: Effects of cannabinoid receptor type 2 on endogenous myocardial regeneration by activating cardiac progenitor cells in mouse infarcted heart. Sci China Life sci 2014; 57: 201-208.
12. Zheng D, Dong S, Li T, Yang F, Yu X, Wu J, Zhong X, Zhao Y, Wang L, Xu C, Lu F, Zhang W: Exogenous hydrogen sulfide attenuates cardiac fibrosis through reactive oxygen species signal pathways in experimental diabetes mellitus models. Cell Physiol Biochem 2015; 36: 917-929.
13. Bache RJ, Chen Y: Nox2-induced myocardial fibrosis and diastolic dysfunction: Role of the endothelium. J Am Coll Cardiol 2014; 63: 2742-2744.
14. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J: Tgf-beta signaling in vascular fibrosis. Cardiovasc Res 2007; 74: 196-206.
15. Kim MJ, Park SA, Kim CH, Park SY, Kim JS, Kim DK, Nam JS, Sheen YY: Tgf-beta type i receptor kinase inhibitor ew-7197 suppresses cholestatic liver fibrosis by inhibiting hiflalpha-induced epithelial mesenchymal transition. Cell Physiol Biochem 2016; 38: 571-588.
16. He T, Bai X, Yang L, Fan L, Li Y, Su L, Gao J, Han S, HuD: Loureirin b inhibits hypertrophic scar formation via inhibition of the tgf-betal-erk/jnk pathway. Cell Physiol Biochem 2015; 37: 666-676.
17. HowdenR: Nrf2 andcardiovasculardefense. OxidMed CellLongev2013; 2013: 104308.
18. Liu W, Wang B, Wang T, Liu X, He X, Liu Y, Li Z, Zeng H: Ursodeoxycholic acid attenuates acute aortic dissection formation in angiotensin ii-infused apolipoprotein e-deficient mice associated with reduced ros and increased nrf2 levels. Cell Physiol Biochem 2016; 38: 1391-1405.
19. Wang Y, Li C, Cheng K, Zhang R, Narsinh K, Li S, Li X, Qin X, Zhang R, Li C, Su T, Chen J, Cao F: Activation of liver x receptor improves viability of adipose-derived mesenchymal stem cells to attenuate myocardial ischemia injury through tlr4/nf-kappab and keap-l/nrf-2 signaling pathways. Antioxid Redox Signal 2014; 21: 2543-2557.
20. Zhou S, SunW, Zhang Z, ZhengY: The role of nrf2-mediated pathway in cardiac remodeling and heart failure. Oxid Med Cell Longev 2014; 2014: 260429.
21. Li X-H, Li C-Y, Xiang Z-G, Hu J-J, Lu J-M, Tian R-B, Jia W: Allicin ameliorates cardiac hypertrophy and fibrosis through enhancing of nrf2 antioxidant signaling pathways. Cardiovasc Drugs Ther 2012; 26: 457-465.
22. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Boucher M, Fan Q, Chuprun JK, Ma XL, Koch WJ: A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res 2010; 107: 1445-1453.
23. Dubey RK, Gillespie DG, Mi Z, Jackson EK: Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: Role of a2b receptors. Circulation 1997; 96: 2656-2666.
24. Chen X, Liu G, Zhang W, Zhang J, Yan Y, Dong W, Liang E, Zhang Y, Zhang M: Inhibition of mef2a prevents hyperglycemia-induced extracellular matrix accumulation by blocking akt and tgf-fil/smad activation in cardiac fibroblasts. Int J Biochem Cell Biol 2015; 69: 52-61.
25. Han D, Huang W, Li X, Gao L, Su T, Li X, Ma S, Liu T, Li C, Chen J, Gao E, Cao F: Melatonin facilitates adipose-derived mesenchymal stem cells to repair the murine infarcted heart via the sirtl signaling pathway. J PinealRes2016; 60: 178-192.
26. Pan Q, Qin X, Ma S, Wang H, Cheng K, Song X, Gao H, Wang Q, Tao R, Wang Y, Li X, Xiong L, Cao F: Myocardial protective effect of extracellular superoxide dismutase gene modified bone marrow mesenchymal stromal cells on infarcted mice hearts. Theranostics 2014; 4: 475-486.
27. Palazuelos J, Ortega Z, Diaz-Alonso J, Guzman M, Galve-Roperh I: Cb2 cannabinoid receptors promote neural progenitor cell proliferationvia mtorcl signaling. J Biol Chem 2012; 287: 1198-1209.
28. Yeh YH, Kuo CT, Chang GJ, Chen YH, Lai YJ, Cheng ML, Chen WJ: Rosuvastatin suppresses atrial tachycardia-induced cellular remodelingvia akt/nrf2/heme oxygenase-1 pathway. J Mol Cell Cardiol 2015; 82: 84-92.
29. van Nieuwenhoven FA, Turner NA: The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul Pharmacol 2013; 58: 182-188.
30. Walters DM, Cho H-Y, Kleeberger SR: Oxidative stress and antioxidants inthe pathogenesis of pulmonary fibrosis: A potential role for nrf2. Antioxid Redox Signal 2008; 10: 321-332.
31. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA: Controversies inventricular remodelling. Lancet 2006; 367: 356-367.
32. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35: 569-582.
33. LiW, Yan S, Zhao J, Ding X, Zhang S, Wang D, Liu L, Peng W, Li H, Wang D, Liu Z, Li Y: Metoprolol inhibits cardiac apoptosis and fibrosis in a canine model of chronic obstructive sleep apnea. Cell Physiol Biochem 2015; 36: 1131-1141.
34. Li Q, Wang F, Zhang Y-M, Zhou J-J, Zhang Y: Activation of cannabinoid type 2 receptor by jwhl33 protects heart against ischemia/reperfusion-induced apoptosis. Cell Physiol Biochem 2013; 31: 693-702.
35. Duerr GD, Heinemann JC, Suchan G, Kolobara E, Wenzel D, Geisen C, Matthey M, Passe-Tietjen K, Mahmud W, Ghanem A: The endocannabinoid-cb2 receptor axis protects the ischemic heart at the early stage of cardiomyopathy. Basic Res Cardiol 2014; 109: 1-15.
36. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J: Myocardial remodeling after infarction: The role of myofibroblasts. Nat Rev Cardiol 2010; 7: 30-37.
37. van Nieuwenhoven FA, Turner NA: The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul Pharmacol 2013; 58: 182-188.
38. Wang K, Liu CY, Zhou LY, Wang JX, Wang M, Zhao B, Zhao WK, Xu SJ, Fan LH, Zhang XJ, Feng C, Wang CQ, Zhao YF, Li PF: Apflncrna regulates autophagy and myocardial infarction bytargeting mir-188-3p. Nat Commun2015; 6: 6779.
39. Zhao X, Wang K, Liao Y, Zeng Q, Li Y, Hu F, Liu Y, Meng K, Qian C, Zhang Q, Guan H, Feng K, Zhou Y, Du Y, Chen Z: Microrna-101a inhibits cardiac fibrosis induced by hypoxia via targeting tgfbetari on cardiac fibroblasts. Cell Physiol Biochem 2015; 35: 213-226.
40. Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, Manin S, DeveauxV, Bourin MC, Zimmer A, Lotersztajn S, Pecker F, Pavoine C: The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J 2009; 23: 2120-2130.
41. Li J, Ichikawa T, Villacorta L, Janicki JS, Brower GL, Yamamoto M, Cui T: Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vase Biol 2009; 29: 1843-1850.
42. Hafstad AD, Nabeebaccus AA, Shah AM: Novel aspects of ros signalling in heart failure. Basic Res Cardiol 2013; 108: 359.
43. Huynh K, Bernardo BC, McMullen JR, Ritchie RH: Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 2014; 142: 375-415.
44. Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y: Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-betal inhypertensive rats. Mol Cell Biochem 2008; 317: 43-50.
45. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, Yamamoto M: Physiological significance of reactive cysteine residues ofkeapl in determining nrf2 activity. Mol Cell Biol 2008; 28: 2758-2770.
46. Xu M, Li XX, Wang L, Wang M, Zhang Y, Li PL: Contribution of nrf2 to atherogenic phenotype switching of coronary arterial smooth muscle cells lacking cd38 gene. Cell Physiol Biochem 2015; 37: 432-444.
47. Li S, Fan Q, He S, Tang T, Liao Y, Xie J: Microrna-21 negatively regulates treg cells through a tgf-betal/smad-independent pathway in patients with coronaryheart disease. Cell Physiol Biochem 2015; 37: 866-878.
48. Todorovic V, Jurukovski V, Chen Y, Fontana L, Dabovic B, Rifkin DB: Latent tgf-beta binding proteins. Int ] Biochem Cell Biol 2005; 37: 38-41.
49. Qi HP, Wang Y, Zhang QH, Guo J, Li L, Cao YG, Li SZ, Li XL, Shi MM, Xu W, Li BY, Sun HL: Activation of peroxisome proliferator-activated receptor gamma (ppargamma) through nf-kappab/brgl and tgf-betal pathways attenuates cardiac remodeling in pressure-overloaded rat hearts. Cell Physiol Biochem 2015; 35: 899-912.
50. Sun C, Li S, Li D: Sulforaphane mitigates muscle fibrosis in mdx mice via nrf2-mediated inhibition of tgf-beta/smad signaling. J Appl Physiol (1985) 2016; 120: 377-390.
51. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ: Nadph oxidase-4 mediates myofibroblastactivation and fibrogenic responses to lung injury. Nat Med 2009; 15: 1077-1081.
52. Liu RM, Gaston Pravia KA: Oxidative stress and glutathione in tgf-beta-mediated fibrogenesis. Free Radic Biol Med2010; 48: l-15.
53. Black D, Lyman S, Qian T, Lemasters JJ, Rippe RA, Nitta T, Kim J-S, Behrns KE: Transforming growth factor beta mediates hepatocyte apoptosis through smad3 generation of reactive oxygen species. Biochimie 2007; 89: 1464-1473.
54. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, Hooker BA, Dart MJ, Sullivan JP, Meyer MD: Invitro pharmacological characterization of aml241: A protean agonist atthe cannabinoid cb2 receptor? BrJPharmacol2006; 149: 145-154.
55. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, Leask A: Prostacyclin derivatives preventthe fibrotic response to tgf-beta by inhibitingthe ras/mek/erk pathway. FASEB ] 2002; 16: 1949-1951.
56. Peake BF, Nicholson CK, Lambert JP, Hood RL, Amin H, Amin S, Calvert JW: Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating nrf2 signaling in an erk-dependent manner. Am J Physiol Heart Circ Physiol 2013; 304: H1215-H1224.
57. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, Sortino MA, Nicoletti F, Copani A, Vancheri C: Tgf-beta 1 targets the gsk-3 beta /beta-catenin pathway via erk activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res 2008; 57: 274-282.